Treatment of Metformin Decreases the Risk of Varicose Vein: A Mendelian Randomization Study

Qinchang Chen,Lingling Li,Ridong Wu,Shenming Wang,Chen Yao
DOI: https://doi.org/10.21203/rs.3.rs-71387/v1
2020-01-01
Abstract:Abstract Background Varicose vein is a common illness of the vascular system which affects life quality and social function of patients. We aimed to assess the causality between metformin and varicose vein using a two-sample Mendelian randomization(MR)analysis based on genome-wide association study (GWAS) summary data.Methods Twenty-five single nucleotide polymorphisms (SNPs) were selected from the GWAS summary data from Neale Lab and MRC-IEU Consortium available on the MR-base platform. Inverse variance weighted (IVW), MR-egger method, weighted median method and weighted mode were adopted. Results were evaluated by pleiotropy test using an Egger regression method and sensitivity analysis preforming a leaving-one-out (LOO) method. Analyses were performed using R package “TwoSampleMR”.Results The result of IVW method showed that one SD increased treatment of metformin was linked with approximately 10% lower risk of varicose vein (OR,0.90; 95%CI, 0.85-0.96; P, 6.99e-04). It was similar to that measured by other methods in the aspect of effect size and direction. There is no evidence to supporting genetic pleiotropy in the MR-Egger regression method (intercept=2.5e-04, P=0.33). No single SNP was detected to be strongly driving the overall causal effect in a LOO sensitivity analysis. The genetically predicted treatment of metformin was negatively casually associated with varicose veins.Conclusions This study suggested that treatment of metformin was a casual protective factor of varicose vein. Further researches are required to confirm our findings and explore the potential mechanisms of metformin on varicose vein.
What problem does this paper attempt to address?